The use of intravitreal bevacizumab in neovascular glaucoma: a case report.
OBJECTIVE
To assess the short-term safety and efficacy of an intravitreal injection of bevacizumab in a patient with neovascular glaucoma.


METHODS
Intravitreal bevacizumab injection was given in a patient with neovascular glaucoma and the changes in the visual acuity, intraocular pressure (lOP), iris neovascularisation were noted before injection and after one day, one week, three weeks and six weeks. Regression of the iris new vessels and normalization of the intraocular pressure was noted.


CONCLUSIONS
Intravitreal bevacizumab was effective and safe in the short-term in a patient with neovascular glaucoma. It may be a useful adjunctive treatment.
Kelkar
A S
AS
National Institute of Ophthalmology, Pune, India.
Kelkar
S B
SB
Kelkar
J A
JA
Nagpal
M
M
Patil
S P
SP
D000368:Aged; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage*; D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D003924:Diabetes Mellitus, Type 2 / Q000150:complications; D015355:Glaucoma, Neovascular / Q000188:drug therapy* / Q000209:etiology; D006801:Humans; D006973:Hypertension / Q000150:complications; D008297:Male; D012074:Remission Induction
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab